Vitiligo Clinical Trial
Official title:
Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Dynamics in Vitiligo
Vitiligo is the most common acquired depigmented disorder of the skin characterized by destruction of melanocytes resulting in well-circumscribed achromic macules. Ultraviolet phototherapy with narrow band (UVB-NB) is currently one of the treatments of choice, because it is able to induce proliferation, differentiation, maturation and migration of melanocytes. This repigmentation has distinctive patterns such as follicular, marginal, and diffuse. The aim of this study is to observe the dynamics of migration and proliferation, in vitiligo patients under UVB radiation phototherapy treatment. The investigators will evaluate this process by measuring FAK (focal adhesion kinase ) and c-Kit by immunohistochemistry and reverse transcriptase polymerase chain reaction assay.
Vitiligo is the most common acquired depigmented disorder of the skin characterized by
destruction of melanocytes, which results in well-circumscribed achromic macules. Its
etiology is not fully recognized but functional melanocytes may disappear by autoimmune
response, oxidative stress that induces melanocytes apoptosis, and loss of cell-cell
adhesion between melanocytes and keratinocytes.
Ultraviolet phototherapy with narrow band (UVB-NB) is currently one of the treatments of
choice with an average response rate of 60-70% on lesions. UVB-NB phototherapy may induce
immune regulation and melanogenic induction. It is also able to induce Treg cells
proliferation to suppress the autoimmune response which destroys melanocytes. By the other
hand, UVB-NB induces signaling of proliferation, differentiation, maturation and migration
of melanocytes, playing an important role in vitiligo re-pigmentation.
Phosphorylation of focal adhesion kinase (p-FAK125) is a cytoplasmic tyrosine kinase that
plays as an important component in the signal transduction of cell migration, as it
modulates cytoskeletal proteins necessary for their movement. UVB-NB radiation induces
migration on melanocytes cultures increasing their levels of p-FAK125 and it has been
proposed as a melanocyte migration marker.
C-kit is a tyrosine kinase receptor expressed on melanoblasts and differentiated
melanocytes. Ligand binding induces PI3K, MAPK and Src kinase pathways, which traduce
differentiation of melanoblast into proliferating melanocytes; so its expression imply the
presence of mature pigmented melanocytes. C-kit is increased in mature melanocytes after UVB
exposure, but it has been show that in melanoma cases the loss of c-kit expression is
involved in cancer progression , therefore c-kit signaling is also associated in migratory
process. Although, different reports have been established the expression of this markers on
vitiligo, is not defined this markers on the repigmentation patterns induces to UVB
radiation.
UVB radiation induces repigmentation in distinctive patterns such as follicular, marginal,
and diffuse. Follicular pattern is the predominant, and comes from hair follicle
melanocytes. In the marginal pattern melanocytes from healthy skin are attracted to the
lesion. In the diffuse pattern UVB radiation stimulates those inactive melanocytes. In
contrast, achromic pattern not induces melanocyte activation. The relation between the
biological behavior of melanocytes and these repigmentation patterns, may provide insights
to an improved method to treat vitiligo. The aim of this study is to observe the dynamic of
migration and proliferation by specific markers on the repigmentation patterns of vitiligo
patients under UVB radiation phototherapy.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |